Vidac Pharma Holding Plc (ETR:T9G)

Market Cap	21.42M
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	51.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,000
Open	0.4040
Previous Close	0.3980
Day's Range	0.3800 - 0.4250
52-Week Range	0.3500 - 0.9600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Vidac Pharma Holding

Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTCL); and VDA-1102 Ointment, an anti-neoplastic agent that is in phase 2B clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Country: United Kingdom
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: T9G

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 28, 2026

Data Sources Report a data error